Tonix Pharmaceuticals Holding (TNXP) Liabilities and Shareholders Equity (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $254.1 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 35.62% year-over-year to $254.1 million in Q2 2026; TTM through Jun 2026 was $1.0 billion, a 63.23% increase from a year earlier, with the FY2025 full-year figure at $277.2 million, up 70.16% from the prior year.
• Liabilities and Shareholders Equity was $254.1 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from $257.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $277.2 million in Q4 2025, with the low at $70.3 million in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $193.7 million, with a median of $190.1 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 55.99% in 2024, then soared 166.49% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $225.7 million in 2022, then plunged by 31.56% to $154.5 million in 2023, then climbed by 5.46% to $162.9 million in 2024, then surged by 70.16% to $277.2 million in 2025, then dropped by 8.33% to $254.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $254.1 million (Q2 2026), $257.9 million (Q1 2026), and $277.2 million (Q4 2025), per Business Quant data.